MSCI finalized a rule effective Nov. 30 that excludes "non-operating companies" from its Global Investable Market Indexes, targeting firms like Michael Saylor's Strategy whose assets are mostly Bitcoin. The rule removes a previous reprieve for companies holding over 50% digital assets and uses financial ratio tests to determine eligibility. This change could force index-tracking funds to sell shares of affected companies, potentially lowering their stock prices. MSCI will publish the list of affected firms on Nov. 11, while companies like Metaplanet and Strategy are adjusting their holdings in response.
The MSCI rule change affecting Bitcoin treasury companies provides context for cryptocurrency market activity on Pluang. For readers following digital assets, here is Pluang's market snapshot as of Oct 17, 2026 01:31 WIB: out of 50 major cryptocurrencies, 19 rose and 30 fell. Notable movers include EOS at Rp12.649 with an 8.13% increase and FIL at Rp20.439 with a 5.37% increase, while XTZ declined by 4.16% to Rp5.512.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
